Overview

Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia

Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy, safety and tolerability of aripiprazole in the treatment of acutely relapsed patients with diagnoses of schizophrenia or schizoaffective disorder with risperidone as an active control.
Phase:
Phase 3
Details
Lead Sponsor:
Taiwan Otsuka Pharm. Co., Ltd
Treatments:
Aripiprazole
Risperidone